|
|
||||||||
Laboratory of Immunobiology, Rega Institute, University of Leuven, Faculty of Medicine, B-3000 Leuven, Belgium
Correspondence: Dr. A. Billiau, Rega Institute, University of Leuven, Laboratory of Immunobiology, Minderbroedersstraat 10, B-3000 Leuven, Belgium. E-mail: Alfons.Billiau{at}rega.kuleuven.ac.be
DBA/1 mice deficient in expressing the interferon-
(IFN-
)
membrane receptor (IFN-
R KO mice) are more susceptible to
collagen-induced arthritis (CIA) than wild-type mice, indicating that
endogenous IFN-
plays a protective role in the pathogenesis of CIA.
In IFN-
R KO mice, nitric oxide (NO) production during CIA is
impaired. Because NO is known to exert immunosuppressive and
anti-inflammatory effects in certain model systems, the protective
effect of IFN-
might be mediated by NO. Here, we tested in wild-type
mice whether inhibition of NO production by metabolic inhibitors,
aminoguanidine (AG) and L-N-(1-iminoethyl)lysine (L-NIL),
could mimic the ablation of the IFN-
receptor. A high-dose regimen
of AG supplied in the drinking water inhibited NO production, disease
development, and anticollagen antibody production but was also
associated with transient body weight loss. At a dose and time regimen
that still inhibited NO production but did not cause body weight loss,
AG failed to affect disease scores. Treatment with L-NIL, which more
specifically than AG affects inducible NO production, caused a slight
increase in anticollagen antibody production although not significantly
affecting disease occurrence. These data indicate that the diminished
capacity of the IFN-
R KO mice to produce NO following immunization
with collagen is unlikely to account for their higher susceptibility to
CIA.
Key Words: interferon-
nitric oxide collagen-induced arthritis
This article has been cited by other articles:
![]() |
O. Hoffmann, C. Mahrhofer, N. Rueter, D. Freyer, B. Bert, H. Fink, and J. R. Weber Pneumococcal Cell Wall-Induced Meningitis Impairs Adult Hippocampal Neurogenesis Infect. Immun., September 1, 2007; 75(9): 4289 - 4297. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-G. Xiao, X.-C. Wu, J.-S. Yang, L.-Y. Xu, X. Liu, Y.-M. Huang, B. Bjelke, and H. Link Therapeutic potential of IFN-{gamma}-modified dendritic cells in acute and chronic experimental allergic encephalomyelitis Int. Immunol., January 1, 2004; 16(1): 13 - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ohtsuka, F. Konno, H. Honda, T. Oikawa, M. Ishikawa, N. Iwase, K. Isomae, F. Ishii, H. Hemmi, and S. Sato PPA250 [3-(2,4-Difluorophenyl)-6-{2-[4-(1H-imidazol-1-ylmethyl) Phenoxy]ethoxy}-2-phenylpyridine], a Novel Orally Effective Inhibitor of the Dimerization of Inducible Nitric-Oxide Synthase, Exhibits an Anti-Inflammatory Effect in Animal Models of Chronic Arthritis J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 52 - 57. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Matthys, S. Hatse, K. Vermeire, A. Wuyts, G. Bridger, G. W. Henson, E. De Clercq, A. Billiau, and D. Schols AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-{gamma} Receptor-Deficient Mice J. Immunol., October 15, 2001; 167(8): 4686 - 4692. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |